Cefroxadine (CGP-9000), an Orally Active Cephalosporin K

Total Page:16

File Type:pdf, Size:1020Kb

Cefroxadine (CGP-9000), an Orally Active Cephalosporin K ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUly 1980, p. 105-110 Vol. 18, No.1 0066-4804/80/07-0105/06$02.00/0 Cefroxadine (CGP-9000), an Orally Active Cephalosporin K. YASUDA,' S. KURASHIGE,2 AND S. MITSUHASHI2* Department ofMicrobiology, School ofMedicine, Gunma University, Maebashi, Gunma,2 and Medical Department, Pharmaceuticals Division, CHIBA-GEIGY Limited, Takarazuka,' Japan Cefroxadine (CGP-9000; CXD), 7,8[D-2-amino-2-(1,4-cyclohexadienyl)-aceta- mido]-3-methoxy-ceph-3-em-carboxylic acid, is a new orally active cephalosporin derivative. The spectrum of antibacterial activity of CXD is identical with that of cephalexin (CEX), but CXD was twofold more effective than CEX against Escherichia coli and Klebsiella pneumoniae. CXD was as stable to penicillinase as CEX, but it was hydrolyzed by cephalosporinase, with a relative rate of hydrolysis similar to that of CEX. The affinities of CXD and CEX to penicillin- binding proteins of E. coli were estimated; the affinity of CXD to penicillin- binding protein lBs was higher than that of CEX. Consistent with this, CXD had more intensive lytic activity than CEX. In vivo antibacterial activities of CXD and CEX were compared using systemic infections of mice with E. coli and K. pneumoniae; CXD was consistently more active than CEX. Although there are many cephalosporins water. A loopful (about 0.005 ml) of diluted culture available that are suitable for parenteral admin- was inoculated by Micro-planter (Kubota, Japan) onto istration, orally active cephalosporins are less agar plates containing a series of serial twofold dilu- tions ofa drug. MIC values were scored after overnight common. Among oral cephalosporins introduced incubation at 37°C. on the market, cephalexin (CEX) is now in wide- The effect of inoculum size was determined by spread use in the treatment of a variety of infec- means of a twofold serial agar dilution method on HI tious diseases. Cefroxadine (CXD) is the dihy- agar. The inocula were overnight cultures diluted in drophenylglycin derivative of a structurally physiological saline to 10-1, 10-3, and 10-5. modified 7-amino-cephalosporanic acid and is The 50% infective dose. Values for 50% infective structurally related to CEX, but possesses anti- dose were determined by the method of Kato et al. bacterial properties that distinguish it from (2). A bacterial culture in peptone water was diluted CEX. This paper presents the in vitro and in to 2 x 103 to 3 x 103 cells per ml with fresh peptone vivo evaluation of CXD. water. HI agar plates containing various concentra- microbiological tions of a drug were prepared, and a 0.1-ml sample of MATERIALS AND METHODS diluted bacterial suspension was spread on each plate. After overnight incubation at 37°C the number of Antibiotics. CXD, 7f?[D-2-amino-2-(1,4-cyclohex- colonies that had grown on the plate were counted. adienyl)-acetamido]-3-methoxy-ceph-3-em-carboxylic The mean growth inhibition was calculated from a acid, is an orally active cephalosporin derivative (Fig. mean number of colonies on five plates at each drug 1) which was synthesized in the Research Laborato- concentration and on five drug-free agar plates. ries, Pharmaceuticals Division, CIBA-GEIGY Lim- Bactericidal activity. An overnight culture of ited, Basel, Switzerland. Other antibiotics were com- each strain in antibiotic medium no. 3 (Difco) was mercial products. diluted to a final concentration of about 104 cells per Test strains. Strains stocked in this laboratory ml with antibiotic medium no. 3 containing a series of were used as standard stock cultures and are from the serial twofold dilutions of a drug. MICs were read after Reference Laboratory of Drug-Resistant Bacteria, incubation at 37°C for 18 h. One loopful of each culture Gunma University. They were originally isolated from tube in the MIC test series was spotted onto drug-free clinical materials. HI agar plates, and after incubation at 37°C for 18 h, Media. Heart infusion (HI) agar (Eiken), HI broth the minimal bactericidal concentrations of antibiotic (Eiken), and antibiotic medium no. 3 (Difco) were were determined as the lower concentration of drug used. Other media were peptone water and medium that prevented visible growth on HI agar plates. An- B. The former consisted of 10 g of polypeptone, 5 g of other method consisted of counting the number of NaCl, and 1 liter ofdistilled water, the latter contained viable cells at appropriate time intervals after addition 2 g of yeast extract, 10 g of polypeptone, 7 g of of drugs. Na2HPO4. 12H20, 2 g of KH2PO4, 1.2 g of glucose, and Stability to /?-lactamase. The enzyme samples 0.4 g of MgSO4- 7H20 in 1 liter of distilled water. were prepared as follows. A 1-ml brain heart infusion In vitro antibacterial activity. Minimal inhibi- culture of each strain was diluted 10-fold with medium tory concentration (MIC) of a drug was determined by B and incubated at 37°C. The cells were harvested by an agar dilution method. Overnight culture in peptone centrifugation, washed with 0.05 M phosphate buffer water was diluted to 106 cells per ml with fresh peptone (pH 7.0), and resuspended in the same buffer. The 105 106 YASUDA, KURASHIGE, AND MITSUHASHI ANTIMICROB. AGENTS CHEMOTHER. cells were disrupted in an ultrasonicator. Enzyme ac- fractionated on a sodium dodecyl sulfate-polyacryl- tivity was photometrically measured (6). All the mea- amide slab gel. The PBPs were detected by fluorog- surements were made at a substrate concentration of raphy with X-ray film (Fuji RHs). The level of [14C] 0.1 mM. The figures in Table 3 are relative values, penicillin G binding to 1A and lBs at each competitor taking the absolute rate of cephaloridine hydrolysis as concentration was quantitated by densitometry of the 100 for cephalosporinase and that of penicillin G hy- X-ray film. drolysis as 100 for penicillinase. In vivo antibacterial activity. The in vivo anti- Pseudomonas aeruginosa ML4259 Rms139+ (7) bacterial activity of CXD was determined by experi- and Klebsiella pneumoniae GN49 were used as the mental infection of mice with gram-negative bacteria. standard strains capable of producing the known types Twenty male mice (ICR strain) weighing 18 to 22 g of penicillinase, and Escherichia coli GN5482, P. were used for each dose level. The mice were chal- aeruginosa GN918 (12), Enterobacter cloacae lenged intraperitoneally with sufficient microorgan- GN7471, and Proteus morganii GN5407 were used for isms to kill all nontreated mice within 48 h. The cephalosporinase. microorganisms were grown on an HI agar plate and PBPs. The affinity of CXD and the comparative suspended in physiological saline solution. Mice in- compound, CEX, to the penicillin-binding proteins fected with E. coli ML4707 and K. pneumoniae (PBPs) was examined. Seven PBPs were detected in GN6445 were treated orally immediately after infec- E. coli JE1011 by the modified method (11) described tion and 3 h later. The total number of surviving mice by Spratt (8). CXD and CEX were used as competitors was recorded, usually 1 week after infection, and the for '4C-labeled penicillin G binding to E. coli PBPs. amount of a single dose (milligrams per kilogram) that The concentrations of competitor added to the reac- gave protection to 50% of the infected mice was esti- tion mixture were 1-, 5-, and 25-fold greater than the mated by means of a log-probit plot (3). concentration of 14C-labeled penicillin G (34 itg/ml). The binding reaction was terminated, and the proteins RESULTS of the inner membrane were selectively solubilized and An.ftnPIfi;&wrIUiho+va1l 5jM%&rU*Qeywt.ium Tha111; DIMLILUaae.twnim V1nf antibacterial activity of CXD against gram-pos- itive and gram-negative bacteria is shown in Table 1. CXD was active against both gram- positive and gram-negative organisms suscepti- -OCH3. 2H2o ble to CEX. Both antibiotics exhibited almost similar effectiveness against gram-positive or- ganisms, but CXD was more active against FIG. 1. Structure of CXD (CGP- 9000). CEX - susceptible gram - negative organisms. TABLE 1. Antibacterial activity of CXD against standard strains of bacteria MIC (g/ml)b Test organisma CXD CEX 106 lol 106 lol Staphylococcus aureus 1.56 3.13 3.13 6.25 FDA209PJC-1 S. aureus E-46 3.13 6.25 6.25 12.5 S. aureus Terajima 1.56 3.13 3.13 6.25 Escherichia coli 3.13 6.25 12.5 12.5 NIHJ-JC-2 Salmonella typhi 901 1.56 3.13 3.13 6.25 S. paratyphi 1015 1.56 3.13 3.13 6.25 S. schottmuelleri 8006 1.56 3.13 3.13 6.25 Klebsiellapneumoniae 1.56 3.13 3.13 6.25 PCI-602 Serratia marcescens >100 >100 >100 >100 L4MI 184 Proteus vulgaris OX-19 >100 >100 >100 >100 P. rettgeri IF03850 >100 >100 >100 >100 P. mirabilisIF03849 6.25 12.5 50 100 Pseudomonas aeruginosa >100 >100 >100 >100 IF03445 aThe tested strains are the standard strain stocked at the Laboratory of Bacterial Resistance, School of Medciine, Gunma University. b Overnight HI broth culture was diluted with physiological saline, and one loopful (0.005 ml) of i06 or 108 cells per ml was inoculated. VOL. 18, 1980 CEFROXADINE 107 Both CXD and CEX acted equally poorly tration of CXD required to inhibit the growth of against Serratia marcescens, Proteus species, 50% of the total number of tested E. coli strains and P. aeruginosa. (MIC50) was 3.13 to 6.25 ,ug/ml, whereas that of Antibacterial activity. The antibacterial ac- CEX was 6.25 to 12.5 ,ug/ml. The MIC50 of CXD tivity of CXD against gram-positive and gram- against K.
Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Table S1: the Experimentally Measured Logp Values (Mlogp) of 154 Drugs Vs
    Table S1: The experimentally measured LogP values (MLogP) of 154 drugs vs. the in-silico calculations of LogP with the different methods MLogP CLogP CLogP ALogP KLogP (BioLoom (BioLoom (ChemDraw (MOE molecular Drug 5.0) 5.0) Ultra 8.0) 2004.03) formula abacavir sulfate 1.22 0.81 0.58 1.09 0.99 acetaminophen 0.51 0.49 0.49 1.35 0.7 acetazolamide -0.26 -0.98 -1.13 -0.86 -1.58 acetylsalicylic acid 1.19 1.02 1.02 1.31 0.36 acyclovir -1.56 -2.42 -2.42 -1.46 -1.03 albendazole 2.85 3.46 3.46 3.24 1.06 allopurinol -0.55 -0.83 0.63 0.06 -0.51 alprazolam 2.12 2.55 2.21 3.58 3.5 amiloride hydrochloride 0.1 0.11 0.11 -1.08 -0.58 amisulpride 1.1 1.8 1.8 1.29 1.32 amitriptyline hydrochloride 4.92 4.85 4.85 4.17 4.47 amlodipine besylate 3.3 3.43 3.43 2.27 2.54 amoxicillin -1.99 -1.87 -1.87 0.02 0.67 amphetamine (mixed salt) 1.76 1.74 1.29 1.58 1.82 artemether 2.86 3.05 3.05 2.84 1.53 ascorbic acid -1.64 -1.76 -1.76 -1.41 -1.28 atenolol 0.16 -0.11 -0.11 0.45 1.33 atropine sulfate 1.83 1.3 1.3 1.93 2.38 azathioprine 0.1 0.11 0.51 0.82 -0.91 azithromycin hydrate 4.02 2.64 na 1.9 2.88 azulene sulfonate sodium 3.2 3.32 2.95 2.79 2.42 benznidazole 0.91 0.9 0.9 0.57 0.26 biperiden hydrochloride 4.25 4.94 4.94 3.96 4.23 bisoprolol fumarate 1.87 1.83 1.92 2.37 2.13 brotizolam 2.79 2.71 2.36 4.4 2.79 captopril 0.9 0.89 0.89 0.63 0.5 carbamazepine 2.19 2.38 2.38 3.39 2.54 carvedilol 4.11 4.04 4.04 3.74 3.32 cefaclor -1.79 -1.64 -1.64 0.62 1.55 cefmetazole sodium -0.6 -1.34 -1.34 -0.73 -0.74 cefroxadine -2.27 -2.15 -1.95 -0.21 0.67 cefuroxime axetil 0.26 0.23 0.23
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Vol. Xxxv No. 7 the Journal of Antibiotics 843 Antibacterial
    VOL. XXXV NO. 7 THE JOURNAL OF ANTIBIOTICS 843 ANTIBACTERIAL EFFECTS OF CEFROXADINE, CEPHALEXIN AND CEPHRADINE IN A NEW IN VITRO PHARMACOKINETIC MODEL P. SCHNEIDER, W. TOSCH, M. MAURER and O. ZAK Research Department, Pharmaceuticals Division, Ciba-Geigy Limited, Basle, Switzerland (Received for publication March 31, 1982) A pharmacokinetic model has been developed, by means of which all possible time courses of the concentrations of antibiotics in the plasma of treated individuals can be exactly simulated in vitro without diluting the test organism and affecting the growth curves. Equi- effective concentrations in the system corresponded to the plasma concentrations in man produced by cefroxadine in a single oral dose of 250 mg and cephalexin and cephradine in a single oral dose of 500 mg. The antibacterial activity of antibiotics in vitro is most commonly assessed by determination of the minimum inhibitory concentrations (MIC) in cultures in which the microorganisms are exposed to con- stant concentrations of the substances for about 18 hours. In vivo, however, antibiotic concentrations change according to the pharmacokinetics of the particular drug. Various in vitro systems have con- sequently been devised in an effort to simulate the time course of antibiotic concentrations in human serum. In the first attempts2•`5), the concentrations were altered in a non-continuous fashion. These were followed by improved techniques6•`14) in which the antibiotics were continuously diluted. In most of the published models, however, the bacterial inoculum is diluted at the same rate as the antibiotic. We have developed a new model employing a filter system by means of which the antibiotic concentrations are varied continuously in an exact simulation of the time course of human serum concentrations, without simultaneous dilution of the bacterial inoculum.
    [Show full text]
  • Revision of Precautions
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Cefmenoxime hydrochloride (preparations for otic and nasal use), chloramphenicol (solution for topical use, oral dosage form), tetracycline hydrochloride (powders, capsules), polymixin B sulfate (powders), clindamycin hydrochloride, clindamycin phosphate (injections), benzylpenicillin potassium, benzylpenicillin benzathine hydrate, lincomycin hydrochloride hydrate, aztreonam, amoxicillin hydrate, ampicillin hydrate, ampicillin sodium, potassium clavulanate/amoxicillin hydrate, dibekacin sulfate (injections), sultamicillin tosilate hydrate, cefaclor, cefazolin sodium, cefazolin sodium hydrate, cephalexin (oral dosage form with indications for otitis media), cefalotin sodium, cefixime hydrate, cefepime dihydrochloride hydrate, cefozopran hydrochloride, cefotiam hydrochloride (intravenous injections), cefcapene pivoxil hydrochloride hydrate, cefditoren pivoxil, cefdinir, ceftazidime hydrate, cefteram pivoxil, ceftriaxone sodium hydrate, cefpodoxime proxetil, cefroxadine hydrate, cefuroxime axetil, tebipenem pivoxil, doripenem hydrate, bacampicillin hydrochloride, panipenem/betamipron, faropenem sodium hydrate, flomoxef sodium, fosfomycin calcium hydrate, meropenem hydrate, chloramphenicol sodium succinate,
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • E-Table 1. Drug Classification Category Name Generic Name
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax e-Table 1. Drug classification Category Name Generic Name Antiplatelets clopidogrel, cilostazol, ticlopidine2, beraprost, beraprost–long acting, complavin Anticoagulants 2,3 dabigatran Statins1,2,3 atorvastatin2, simvastatin, pitavastatin, fluvastatin, pravastatin, rosuvastatin, amlodipine/atorvastatin Sodium channel blockers4,5† mexiletine, aprindine, cibenzoline Beta blocker acebutolol2 Class III antiarrhythmic drugs amiodarone1–6 Calcium channel blockers bepridil1, amlodipine/atorvastatin, telmisartan/amlodipine, valsartan/amlodipine, valsartan/cilnidipine, candesartan/amlodipine Angiotensin/converting enzyme enalapril inhibitor2‡ Thiazides trichlormethiazide, hydrochlorothiazide3,5, benzylhydrochlorothiazide/reserpine/carbazochrome, mefruside, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, candesartan/hydrochlorothiazide, candesartan/trichlormethiazide, losartan/hydrochlorothiazide NSAIDs diclofenac2, celecoxib, loxoprofen, etodolac, nabumetone, pranoprofen Anti-rheumatics actarit, iguratimod, tofacitinib, penicillamine2–5, leflunomide1,3, sodium aurothiomalate2–6#, bucillamine Leukotriene receptor antagonist2* pranlukast 5-ASA mesalazine, salazosulfapyridine5 Tricyclic antidepressant Imipramine5, cromipramine, maprotiline Antiepileptics valproate, phenytoin2,3,5, ethotoin, carbamazepine2–5, zonisamide Interferon1,2,3
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]